Core Points - Kaldvík AS held an extraordinary general meeting on 4 July 2025 to discuss a proposal for an investigation [1][2] - Approximately 83.34% of shares entitled to vote were present, with 76.32% voting against the proposal and 23.68% in favor [2] - Shareholders have the right to request the district court to open an investigation within one month following the general meeting [2] Company Information - The extraordinary general meeting took place at 12:00 hours (CEST) on 4 July 2025 [2] - A copy of the minutes from the meeting is attached to the announcement [2][3] - Contact information for the CEO and CFO is provided for further inquiries [3]

与很多技术驱动型的视频生成模型不同，百度MuseSteamer 的研发启动并非技术驱动，是被广告主用需 求"催生"出来的。 "去年年初行业就在卷视频生成模型，我们不是没看，但真正推动自研的，是商业体系收到的具体需 求。"陈一凡回忆道，2024年年底短剧投流市场爆发，传统剪辑和生图已无法满足创意需求，就有代理 商和广告主向百度提出："能不能用短剧内容做剪辑？""科幻场景拍不出来，能生成吗？" 面对这些需求，百度商业团队曾有两个选择：接入外部模型，或自己动手。但当他们尝试反馈优化建议 时，却发现外部模型迭代周期太长。于是今年春节后，团队决定自研，项目代号就是"MuseSteamer"。 在百度MuseSteamer的自研过程中，不只是短剧行业，更多的行业客户向百度反馈"希望能用大模型提高 广告质量"。 陈一凡表示，由百度商业研发团队推出的MuseSteamer正是来自这些需求的推动。"今天演示的视频偏动 漫类型，其实是大概一个多月前，有客户想用类似动漫的方式去展现创意广告，百度大概用了一个多月 的时间补足动漫类数据，对模型进行了调整。还有，当发现广告创意需要更丰富的运镜时，团队两周内 就研发出运镜语言模型，教会A ...

Financial Performance & Guidance - Henry Schein reported FY2022 global net sales of $12.6 billion[8] - In Q1, GAAP diluted EPS was $0.91, and non-GAAP diluted EPS was $1.21[14] - Total sales growth was -3.8% (LCI -3.7%), but excluding PPE & COVID-19 Test Kits, LCI sales growth was strong at 6.3%[18] - EPS was negatively impacted by an estimated $0.24 due to lower contribution from PPE products and COVID-19 Test Kits, $0.04 from acquisition-related expenses, and $0.02 from foreign exchange[18] Henry Schein One & Dental Technology Market - Henry Schein One's 2022 revenue from dental practice management was approximately $550 million[20, 21] - The estimated dental technology market size is $2.3 billion, with an estimated market growth rate of 8-12%[26] - Henry Schein One has 100,000 active dental customers[26] Strategic Priorities & Market Trends - Henry Schein's strategic priorities include building complementary software, specialty, and services, operationalizing One Distribution, leveraging One Schein, and driving digital transformation[9] - Industry trends driving demand for Henry Schein One solutions include payment & claims innovation (72% of dentists are concerned with declining insurance reimbursement rates), AI & clinical decision support, customer dynamics (consumerization of healthcare), and dental practice consolidation[29, 30]

报告要点： 2025 年 7 月 4 日 A 股冲高回落，大金融领涨。上证指数上涨 0.32%，深 证成指下跌 0.25%，创业板指下跌 0.36%。市场成交额 14283.65 亿元，较上 一交易日增加 1187.78 亿元。全市场 1197 只个股上涨，4160 只个股下跌。 风格上看，各指数涨跌幅排序为：金融>稳定>消费>0>成长>周期；大盘 价值>小盘价值>大盘成长>中盘价值>中盘成长>小盘成长；基金重仓表现优 于中证全指。 分行业看，30 个中信一级行业涨跌互现；表现相对靠前的是：银行 （1.85%），综合金融（1.13%），传媒（0.72%）；表现相对靠后的是：有色金 属（-1.49%），基础化工（-1.38%），轻工制造（-1.14%）。概念板块方面， 多数概念板块下跌，重组蛋白、昨日涨停、退税商店等大幅上涨；噪声防 治、昨日触板、电子烟等大幅走低。 证券研究报告 9[Table_Title] 每日复盘 2025 年 7 月 4 日 2025 年 7 月 4 日 A 股冲高回落，大金融领涨 资金筹码方面，主力资金 7 月 4 日净流出 336.46 亿元。其中超大单净流 出 118.79 亿元， ...

Tovecimig Clinical Trial Results (COMPANION-002 Study) - The COMPANION-002 study is a Phase 2/3 registrational-intent study in patients with BTC who have received one prior line of therapy[9] - In the Intent-to-Treat population, the Overall Response Rate (ORR) for Tovecimig + Paclitaxel was 17.1% (19 out of 111 patients) compared to 5.3% (3 out of 57 patients) for Paclitaxel alone, with a two-sided p-value of 0.031[12] - The Complete Response (CR) rate in the Tovecimig + Paclitaxel arm was 0.9% (1 out of 111 patients), while the Partial Response (PR) rate was 16.2% (18 out of 111 patients)[12] - Stable Disease (SD) was observed in 44.1% of patients (49 out of 111) in the Tovecimig + Paclitaxel arm compared to 33.3% (19 out of 57) in the Paclitaxel arm[12] - Progressive Disease (PD) was observed in 16.2% of patients (18 out of 111) in the Tovecimig + Paclitaxel arm compared to 42.1% (24 out of 57) in the Paclitaxel arm[12] Tovecimig Development and Potential - Tovecimig is a bispecific antibody targeting DLL4 and VEGF-A, designed to disrupt tumor vessel formation and angiogenesis[6, 7] - The company anticipates top-line Phase 2/3 data for PFS, OS, and DoR in Q4 2025[25] - Tovecimig has the potential to become a standard of care in 2L BTC, with PFS, OS and DoR data expected in Q4 2025[18] Market and Unmet Needs - There are significant unmet needs in current treatments for BTC, with approximately 85% of 2L patients having limited treatment options[19, 20] - Incidence of BTC is significant, with an estimated ~23,000 cases annually[22] - Projected ~100,000 incidence of liver and intrahepatic bile duct cancer by 2040[23]

Financial Performance & Growth - Full Year Fiscal 2025 total sales reached $1.911 billion, demonstrating an 18% five-year Compound Annual Growth Rate (CAGR)[13] - Full Year Fiscal 2025 Consolidated Same Store Sales (SSS) increased by 5.5%[14] - Full Year Fiscal 2025 Earnings Per Share (EPS) reached $5.88[16] - The company anticipates total sales of $2.15 billion for Fiscal Year 2026[24] Strategic Initiatives - The company is focused on four strategic initiatives: New Stores, Same Store Sales, Omni-Channel, and Merchandise Margin & Exclusive Brands[11] - The company aims for 15% annual growth in new stores[33, 34, 35] - New stores have strong economics, with an average payback period of approximately 1.8 years and approximately 53% cash on cash return in the first year of operation[40, 41] - The company is targeting marketing spend at 3% of sales, with incremental spending focused on more content distribution in Fiscal 2026[51] Merchandise & Tariffs - Exclusive brands account for approximately 35% of sales volume[61] - The company estimates an $8 million tariff impact on Exclusive Brands merchandise Cost of Goods Sold (COGS) for Fiscal Year 2026 due to tariffs[69] Market & Competition - The company operates within a total addressable market (TAM) of approximately $40 billion[6] - The company faces competition from national and regional retailers, independent retailers, farm & ranch competitors, and online/direct-to-consumer competitors[8]

PBFT02 Development and Preclinical Results - PBFT02 is an AAV gene therapy designed to deliver functional PGRN to the brain for the treatment of FTD-GRN [13] - In Grn-/- mice, AAV.hGRN vector ICV administration improved lysosomal function, reduced lipofuscin fluorescence in the thalamus, and reduced brain hexosaminidase activity [21, 23] - AAV1 was selected as the vector serotype due to superior hPGRN levels in CSF compared to AAV5 and AAVhu68 in NHPs [28, 29] - In Grn-/- mice, PBFT02 reduced lipofuscin deposition and neuroinflammation in the brain after intra-CSF delivery [34, 37] - ICM administration of PBFT02 enables PGRN delivery throughout the CNS [40] - In NHPs, PBFT02 dose-dependently increased PGRN in CSF up to day 14 [46, 48] - In NHPs, PBFT02 at Dose 1 resulted in approximately 10e4 GC/ug DNA throughout the brain [43] Clinical Trial (upliFT-D) and Safety - The upliFT-D trial is a global Phase 1/2 multi-center, open-label, dose-escalation study with PBFT02 [52, 55] - FTD-GRN Cohort 1 (n = 5) dosing is complete [56] - All four Cohort 1 participants who received a revised immunosuppression regimen had no SAEs or significant immune responses [57] - Cohort 1 interim data shows PBFT02 administration leads to robust and sustained increases in CSF PGRN [58]

渗漏，这个困扰中国30%老旧住宅的"建筑癌症"，曾是无数家庭的噩梦。墙面霉斑蔓延、天花板渗水， 背后更是建筑结构的安全隐患。而更令人心寒的是维修市场的乱象：坐地起价、偷工减料、售后无门。 2006年，东方雨虹一脚踏进这片泥潭，发起"服务百姓 拒绝渗漏"公益活动，自此，这场公益长跑一跑 就是十九年。 十九年间，这支队伍从科普讲座起步，逐渐进化成一支专业化部队。他们建立工程师认证体系，在全国 开展"理论+实操+现场"三位一体培训。这些"防水特种兵"掌握着对抗南方雨季防潮、北方干燥抗裂的区 域化方案，背包里装着从基层处理到卷材铺贴的标准化流程。当居民看到工程师胸前闪亮的"雨虹服 务"标志时，焦虑的眼神逐渐变得安心——这枚徽章背后是上千次节点处理训练和材料配比考核。 当北京女足队员在绿茵场上奔跑，球衣上"东方雨虹"的字样随身影跃动；当南京红庙小区的老师傅看着 自家修葺一新的屋顶，紧锁的眉头终于舒展；当加纳体育场的工人们铺下最后一道防水卷材，中国制造 成为质量口碑——这些看似不相关的画面，被一家中国建材企业用三十年时间，写成一部关于责任与价 值的自白书。这家企业，便是东方雨虹。 但东方雨虹的向善基因不止于修补裂缝。走进 ...

更令人欣喜的是，近年来亲近自然风潮的兴起，正在全社会播撒下人与自然和谐共生的种子。以观鸟活 动为例，越来越多的爱好者拿起望远镜，观察这些精灵的千姿百态，聆听它们的歌声，感受生命的奇妙 与坚韧，从中收获心灵的宁静与对自然的深刻体悟。这种"不接触的互动"，有利于培养生态保护意识， 让爱鸟护鸟、尊重生命从口号变成越来越多人的自觉行动。 鸟类振翅飞翔的天空，也是我们共享的蓝天。守护"会飞的邻居"，就是守护生物多样性，守护我们赖以 生存的绿水青山。 （新华社上海7月4日电） 鸟类，是我们身边"会飞的邻居"，它们不仅点缀城市生活，更对维护生态系统平衡和稳定发挥着重要作 用，是自然界不可或缺的精灵。强化保护措施，增强爱鸟护鸟意识，守护好这份大自然的神奇与美好， 是全社会共同的责任。 守护"会飞的邻居"，要坚决打击非法猎捕贩卖国家保护鸟类等犯罪行为。中国野生动植物种类多，活动 和分布范围广，少数地方乱捕、滥猎、滥食鸟类等野生动物的现象仍时有发生，威胁野生鸟类等种群安 全。对此，要加大执法力度，推进部门联动，借助高科技手段，坚持对非法猎捕、收购、运输、出售野 生鸟类犯罪全环节打击，坚决斩断违法犯罪链条。 守护"会飞的邻居"，要 ...

Core Insights - BlackRock, Inc. has updated its shareholding in DSV A/S, indicating a change in its ownership percentage of shares and voting rights [1] Shareholding Changes - BlackRock's share capital and voting rights in DSV increased from 5.02% to 5.44% as of July 1, 2025 [1] - The share capital and voting rights held through financial instruments decreased from 0.73% to 0.09% [1] - Overall, BlackRock's total share capital and voting rights in DSV changed from 5.76% to 5.53% [1] - As of July 1, 2025, BlackRock controls a total of 13,316,782 shares/voting rights in DSV, representing 5.53% of the entire share capital and voting rights [1]